Table 1. Baseline characteristics of patients.
| Characteristic | Values |
|---|---|
| n | 120 |
| Age (years), median (IQR) | 69.0 (59.0–79.0) |
| Male, n (%) | 71 (59.2) |
| Cerebrovascular risk factors, n (%) | |
| Arterial hypertension | 91 (76.0) |
| Atrial fibrillation | 28 (23.3) |
| Hyperlipidaemia | 75 (62.5) |
| Diabetes mellitus | 36 (30.0) |
| Previous stroke | 37 (30.8) |
| Smoking, n (%) | |
| Non-smoker | 63 (52.5) |
| Previous smoker | 15 (12.5) |
| Active smoker | 30 (25.0) |
| Undetermined | 12 (10.0) |
| Serum glucose (mmol/L), median (IQR) | 6.4 (5.5–7.8) |
| C-reactive protein (mg/L), median (IQR) | 3.1 (1.5–5.7) |
| INR, median (IQR) | 1.0 (0.9–1.0) |
| Current drug use, n (%) | |
| Antihypertensive therapy | 84 (70.0) |
| Antiplatelet drug* | 52 (43.3) |
| Lipid-lowering therapy | 34 (28.3) |
| Undetermined | 8 (6.7) |
| Thrombin generation parameters, median (IQR) | |
| Lagtime (min) | 3.7 (3.0–4.2) |
| ETP (nM x min) | 1482.0 (1266.0–1785.0) |
| Peak Thrombin (nM) | 258.0 (204.7–315.3) |
| Time to Peak (min) | 7.2 (6.3–8.4) |
| StartTail (min) | 23.7 (21.8–25.4) |
| Velocity Index (nM/min) | 73.3 (50.2–101.9) |
IQR: interquartile range, INR: international normalized ratio, ETP: Endogenous Thrombin Potential.
*Aspirin or P2Y12 inhibitor treatment or both.